课题基金 / 基金详情

Analysis and assessment of relationship between the expression levels of ras oncogane product p21 in carcinomas of oral mucosa and their clinical tuma status

Analysis and assessment of relationship between the expression levels of ras oncogane product p21 in carcinomas of oral mucosa and their clinical tuma status
口腔黏膜癌ras癌基因产物p21表达水平与临床肿瘤状态的关系分析与评估
批准号:
62570901
负责人:
AZUMA Masayuki
金额:
$1.22万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1987
资助国家:
日本
项目状态:
已结题
起止时间:
1987 至 1988

项目摘要

项目成果

AZUMA Masayuki的其他基金

相关文献

中文摘要
翻译
1.采用单抗和免疫组织化学方法检测了121例头颈部鳞状细胞癌组织切片中ras-p21的表达。在121例患者中,59例ras-p21染色阳性。44例口腔白斑和58例正常口腔粘膜均未见阳性染色。对43例患者,其中27例治疗后无瘤,随访至少5年,16例死亡病例,分析ras-p21在原发灶的表达及临床预后与临床病理的关系。43例患者ras p21表达在P&lt;0.001有明显的不良预后。对121例患者进行组织学分级分析,I+II级和III级的ras p21表达分别为P&lt;0.05和P<0.0005,预后显著不良。Ras p21表达与…预后不良的相关性临床分期以III期(P&lt;0.005)和III+IV期(P&lt;0.005)明显。Ras p21在原发灶中的表达与区域淋巴结平衡的关系经统计学检验有统计学意义(p&lt;0.06)。此外,ras p21在43例患者中的表达与烟草的使用有显著关系。结论:1.头颈部鳞状细胞癌组织中ras p21的表达与肿瘤的临床病理状态及临床转归有关。应用免疫组织化学和免疫印迹法检测鼻窦鳞状细胞癌新鲜组织中ras癌基因产物p21的表达。结果显示,ras p21在预处理时的组织切片中呈强阳性染色。然而,肿瘤组织中ras p21的含量在癌症治疗完成后明显减少,与呃逆物质相比。这些结果提示,可以通过ras p21在肿瘤组织中的表达来评估某些癌症治疗的效果。人涎腺鳞癌细胞系HSG高水平表达ras癌基因p21。当HSG细胞与二丁基环腺苷(db-cAMP)共同培养时,HSG细胞的集落形成能力随db-cAMP浓度的增加而受到抑制。此外,与未处理的HSG细胞相比,经处理的HSG细胞中ras p21的表达降低。此外,还发现HSG细胞内dB-cAMP浓度与细胞内cAMP浓度之间存在显著的相关性。较少
英文摘要
1. We examined the expression of ras p21 in tissue sections from 121 patients with squamous cell head and neck cancer using monoclonal antibody and immunohisto chemical nethod. Among the 121 patients examined, 59 specimens showed positive staining ras p21. On the hand, no 44 oral leukoplakies and 58 normal mucosae were seen to be positivaly stained. A total of 43 patients including 27 treated, tumor-free cases, who have been follored for at least 5 years and 16 dead cases, were analyzed for the relationship hetween ras p21 expression in the primary tumor sites and clinical outcome in relation to the clinico pathological tumor status. The expression of ras p21 in 43 patients was significantly poor prognesis at p<0.001. When 121 patients were analyzed in relation to the histological graling, ras p21 expression in grade I+II and grade III was significantly poor prognosis at p<0.05 and p.0.0005, respectively. In addition, correlation hetween ras p21 expression and poor prognosis with regar … More d to the clinical staging was signifiasnt in stage III (p<0.05) and stage III+IV (p<0.005). The examination of relationship hstween ras p21 expression in the primary tumors and regional lyngsh node netostasis resulted in statistical significance (p<0.06). Moreover, expression of ras p21 in the 43 pateints showed significant relation with tohacco use. These findings suggest that ras p21 expression in squamous cell head and neck cancer tissue is conelated with the clinico pathological tumor status and clinical outcome.2. Ras oncogene product p21 expression in fresh tumor tissue from a squamous cell careinoma of the naeillary sincos was examined by the use of immunoparoxidase staining and immunoflotting. As a consequence, expression of ras p21 in tissue sections taken at pretreatment time showed strongly positive stain. However, the content of ras p21 present in the tumor tissues obtained after completion of cancer treatment was markedly reduced, when compared with the hicpsy material. These findiags indicate that effect of some cancer therapy could he estimated from ras p21 expression in tumor tissues.3. A human salivary qland sdenecarinoma cell line, HSG, expresses ras oncogend p21 at a high level. When HSG cells were cultured in the presence of dibutyigl cyclic AMP (dB-cAMP), it was shown that colonyforming ability of HSG cells was suppressed in accordance with the concentration of added dB-CAMP. In additon, ras p21 expression in the treated HSG cells was reduced, when compared with the untreated HSG cells. Moreover, it was found that conelation hetween the concentralions of dB-CAMP and intracellular cAMP in the HSG cells was statistically significant. Less
期刊论文(15)
专著(0)
科研奖励(0)
会议论文
Masayuki Azuma: "The relation of ras oncogone product p21 expression to clinicopathological status criteria and clinical outcome in squamous cell head and neck carcer" The Cancer J.1. 375-380 (1987)
Masayuki Azuma:“鳞状细胞头颈癌中 ras 癌基因产物 p21 表达与临床病理状态标准和临床结果的关系”The Cancer J.1。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Masayuki Azuma: Cancer Res.47. 2898-2903 (1988)
东雅之:癌症研究 47。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
東雅之: 日本虚空外科学会雑誌. 33. 1710-1716 (1987)
Masayuki Azuma:日本虚空外科学会杂志 33. 1710-1716 (1987)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 12 条
    Development of a novel treatment for Sjogren's syndrome on the basis of the regulation of molecules related to the syndrome
    • 批准号:
      17K11842
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2017
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    Development of the microbial catalyst suitable for a bio-fuel cell by integrating superior functions in Escherichia coli
    • 批准号:
      26420797
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.24万
    • 财政年份:
      2014
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    A novel histopathology of oral lichen plans and its therapeutic strategy
    • 批准号:
      24659896
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2012
    • 负责人:
      AZUMA Masayuki
    • 依托单位:
    Study to raise the performance of the glucose fuel cell "Improvement of the electronic acquisition technology from the microbe in the fuel cell"
    • 批准号:
      22560773
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2010
    • 负责人:
      AZUMA Masayuki
    • 依托单位: